Scartozzi, Mario
 Distribuzione geografica
Continente #
NA - Nord America 767
EU - Europa 244
AS - Asia 100
AF - Africa 65
SA - Sud America 1
Totale 1.177
Nazione #
US - Stati Uniti d'America 753
SE - Svezia 87
IT - Italia 57
SG - Singapore 49
CI - Costa d'Avorio 43
CN - Cina 28
GB - Regno Unito 24
AT - Austria 21
BG - Bulgaria 20
DE - Germania 18
SN - Senegal 15
CA - Canada 14
VN - Vietnam 14
NG - Nigeria 5
HK - Hong Kong 4
ES - Italia 3
FR - Francia 3
TR - Turchia 3
BE - Belgio 2
CZ - Repubblica Ceca 2
EG - Egitto 2
FI - Finlandia 2
RO - Romania 2
RU - Federazione Russa 2
AR - Argentina 1
IN - India 1
JP - Giappone 1
UA - Ucraina 1
Totale 1.177
Città #
Chandler 106
Fairfield 82
Woodbridge 64
Ashburn 53
Abidjan 43
Wilmington 35
Houston 34
Cambridge 31
Seattle 31
New York 30
Princeton 25
Lawrence 22
Florence 21
Vienna 21
Sofia 20
Medford 17
Dakar 15
Bremen 14
Ann Arbor 13
Ottawa 13
London 12
Singapore 12
San Diego 11
Council Bluffs 10
Kent 10
Boardman 7
Dearborn 7
Des Moines 7
Dong Ket 6
Serra 6
Lagos 5
Nanjing 5
Redwood City 5
Hong Kong 4
Milan 4
Ogden 4
Seacroft 4
Beijing 3
Bitonto 3
Guangzhou 3
Hebei 3
Izmir 3
Lancaster 3
Murcia 3
Nanchang 3
Phoenix 3
Turin 3
Abbiategrasso 2
Brussels 2
Center 2
Changsha 2
Frankfurt am Main 2
Norwalk 2
Pisa 2
Redmond 2
Washington 2
Cento 1
Chengdu 1
Duncan 1
Edmonton 1
Elk Grove Village 1
Hefei 1
Hyderabad 1
Jacksonville 1
Jiaxing 1
Kunming 1
Lappeenranta 1
Los Angeles 1
Ninh Binh 1
Pistoia 1
Shenyang 1
Verona 1
Wuhan 1
Totale 874
Nome #
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 120
Natural history of malignant bone disease in hepatocellular carcinoma: Final results of a multicenter bone metastasis survey 102
Multicenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib. An INNOVATE Study Protocol 95
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 80
Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies 80
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: A fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis 69
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? [Ann Oncol, 23, 9, (2012) (2313-2318)] doi: 10.1093/annonc/mdr623 65
Cholangiocarcinoma: new perspectives for new horizons 53
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 52
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 45
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 44
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 40
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 37
Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: Results of the multicenter prospective INNOVATE study 37
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis 37
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 36
Erratum to: Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy (The Oncologist, (2017), 22, 12, (1463-1469), 10.1634/theoncologist.2017-0158) 34
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 33
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 32
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 31
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer 29
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 28
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis 10
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 5
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 5
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 5
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 5
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 5
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients 5
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 5
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 4
Totale 1.228
Categoria #
all - tutte 5.879
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.879


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020164 0 6 9 12 38 21 25 20 18 6 5 4
2020/202167 4 7 5 4 2 9 2 6 4 4 3 17
2021/2022194 3 8 4 1 11 53 3 11 5 22 22 51
2022/2023413 40 62 33 24 42 46 6 26 93 2 33 6
2023/2024180 14 15 24 4 21 26 16 14 7 1 15 23
2024/202552 2 50 0 0 0 0 0 0 0 0 0 0
Totale 1.228